Natera (NASDAQ:NTRA) Announces Earnings Results

Natera (NASDAQ:NTRA) posted its quarterly earnings data on Tuesday. The medical research company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.31, Briefing.com reports. The firm had revenue of $439.80 million for the quarter, compared to analysts’ expectations of $361.43 million. Natera had a negative return on equity of 26.88% and a negative net margin of 14.01%. The business’s quarterly revenue was up 63.9% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.95) EPS. Natera updated its FY 2024 guidance to EPS.

Natera Stock Down 0.5 %

Shares of NTRA opened at $160.13 on Thursday. Natera has a 52-week low of $52.01 and a 52-week high of $167.79. The company has a market cap of $19.80 billion, a PE ratio of -91.46 and a beta of 1.53. The company has a quick ratio of 4.01, a current ratio of 4.14 and a debt-to-equity ratio of 0.34. The business has a fifty day moving average of $126.04 and a 200 day moving average of $114.84.

Insider Transactions at Natera

In other Natera news, CFO Michael Burkes Brophy sold 1,866 shares of the firm’s stock in a transaction dated Thursday, October 31st. The shares were sold at an average price of $126.45, for a total value of $235,955.70. Following the completion of the sale, the chief financial officer now owns 68,851 shares of the company’s stock, valued at $8,706,208.95. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CFO Michael Burkes Brophy sold 1,866 shares of the company’s stock in a transaction dated Thursday, October 31st. The shares were sold at an average price of $126.45, for a total value of $235,955.70. Following the transaction, the chief financial officer now directly owns 68,851 shares in the company, valued at approximately $8,706,208.95. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Jonathan Sheena sold 2,700 shares of Natera stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $127.57, for a total transaction of $344,439.00. Following the sale, the insider now owns 284,741 shares of the company’s stock, valued at $36,324,409.37. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 29,881 shares of company stock worth $3,733,983. 7.60% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on NTRA shares. Craig Hallum lifted their price target on shares of Natera from $121.00 to $157.00 and gave the company a “buy” rating in a report on Wednesday. StockNews.com downgraded shares of Natera from a “hold” rating to a “sell” rating in a report on Thursday. JPMorgan Chase & Co. raised their price target on Natera from $135.00 to $160.00 and gave the company an “overweight” rating in a report on Wednesday. Sanford C. Bernstein upped their price objective on Natera from $125.00 to $135.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 30th. Finally, Morgan Stanley lifted their target price on Natera from $125.00 to $132.00 and gave the company an “overweight” rating in a research note on Tuesday, August 13th. One analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $135.06.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.